Furthermore, increased availability of treatments suitable for nmCRPC can be expected to further improve patient outcomes; examples include apalutamide, an androgen receptor inhibitor approved by NICE in September 2021, including for the treatment of high-risk prostate cancer which no longer responds to hormone therapy24. The gene discussed is AR; the disease is prostate cancer.